Fighting Alzheimer’s: New Hope in a New Year Through Innovation
(Page 2 of 2)
of dementia, you were usually diagnosed with Alzheimer’s. The problem is that other types of dementia, like those related to clogged arteries or Lewy Body dementia, require different treatments than Alzheimer’s patients. More precise classification of symptoms means better treatment and outcomes.
3. Better biomarkers: So, how do we get the right diagnosis? The answer is advanced biomarkers. For a long time, doctors and researchers would rely on cognitive measurements, like memory tests, to diagnose Alzheimer’s. These tests can be subjective and therefore imprecise. Biomarkers are a more accurate, physical diagnostic approach, and include genetic profiling, cerebrospinal fluid analysis as well as brain imaging from PET and MRI scans. Checking multiple biomarkers in a patient increases the accuracy of diagnosis. For example, while a gene called ApoE4 is associated with Alzheimer’s, not all people with the ApoE4 will get the disease. Using a multiple-gene profile, combined with a cerebrospinal fluid examination to detect the presence of beta-amyloid or tau proteins and brain volume studies improves the likelihood of a correct diagnosis.
4. Smarter tools and tactics for doctors: Alzheimer’s is deadly serious and doctors need the tools to diagnose and treat it as they would any other serious illness. In fact, what’s good for your heart in fighting heart disease, including a healthy diet and exercise routine, are the same things that will get more blood to the brain and potentially inhibit the onset of Alzheimer’s. Doctors are beginning to see the value of communicating such knowledge to patients, as well as testing for baseline cognitive function as part of an annual routine checkup.
5. Fighting the cause, not the effects: Perhaps the most important trend in Alzheimer’s therapy is the move away from treatments that relieve or delay symptoms in favor of treatments that target the causes of the disease itself. This new approach includes the use of “disease-modifying” drugs designed to combat the disease process by slowing or preventing the excessive accumulation of amyloid proteins or tau protein tangles in the brain. Other therapies in development might even restore cognitive function by removing plaques and tangles that have already formed.
The complexity of Alzheimer’s disease is as profound as the suffering it causes. But this fact must be as much a call to action as cause for despair. Researchers at Proteotech and other companies across America have taken this initiative to heart. That’s why we will continue to make progress and have reason for hope in our fight against this disease in 2011.